Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials

Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials

Monoclonal antibodies (mAbs) that block the programmed death 1 (PD-1) or programmed death-ligand 1 (PD-L1) receptors are the most clinically advanced tumor immunotherapies. Given the broad antitumor efficacy and novel mechanism of action, numerous combinatorial approaches incorporating PD-1/PD-L1 bl...

Full description

Bibliographic Details
Main Authors: C. Bryce Johnson, Shwe Y. Win
Format: Article
Language:English
Published: Taylor & Francis Group 2018-04-01
Series:OncoImmunology
Subjects:
cancer immunotherapy
clinical trials
pd-1
pd-l1
t cell checkpoint inhibitors
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1408744

Internet

http://dx.doi.org/10.1080/2162402X.2017.1408744

Similar Items